From 56d311f8ae3a9d5d3499629365be1615428fc1ed Mon Sep 17 00:00:00 2001
From: ljl-covid <62215844+ljl-covid@users.noreply.github.com>
Date: Mon, 22 Feb 2021 20:15:48 +0100
Subject: [PATCH] Add Scottish paper on efficacy against hospitalization

PDF also available from the government at https://www.ed.ac.uk/files/atoms/files/scotland_firstvaccinedata_preprint.pdf
---
 README.md | 1 +
 1 file changed, 1 insertion(+)

diff --git a/README.md b/README.md
index 84d1a28..8e147e0 100644
--- a/README.md
+++ b/README.md
@@ -297,6 +297,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [The COVID-19 vaccine development landscape](https://www.nature.com/articles/d41573-020-00073-5), published on Nature on April 9, presenting charts with breakdowns of vaccine types under study and their profit models
 * [The Vaccine Tightrope](https://blogs.sciencemag.org/pipeline/archives/2020/10/21/the-vaccine-tightrope) by Derek Lowe analyzes the problem of vaccines being deployed before trials for other vaccines are over, as well as of providing placebo arms with the actual vaccine before the full trial length of two years is completed, with ethical and practical repercussions on participants
 * [mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants](https://www.nature.com/articles/s41586-021-03324-6#article-info) reports on immune response of recipients of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines and notes that activity of their serum against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin
+* [Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264) shows that the Pfizer/BioNTech (BNT162b2) vaccine was associated with a vaccine effect of 85% against hospitalization at 28-34 days post-vaccination, while the effect of the Oxford/Astrazeneca (ChAdOx1) vaccine was 94%, although the age cohorts in the two vaccines were different, and the efficacy against hospitalization was similar for the two vaccines, at 81%, when looking at people over 80
 
 
 #### Moderna (mRNA-1273)